Prostate Cancer

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.

How to best pair immune checkpoint inhibitors with other agents known to have efficacy in genitourinary cancers was a key avenue of inquiry of many of the studies presented at the 2020 Genitourinary Cancers Symposium.

Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Eugene B. Cone, MD, urologist, Massachusetts General Hospital, discusses the cardiac toxicity associated with gonadotropin-releasing hormone (GnRH) agonists in prostate cancer.

Julie N. Graff, MD, discusses the results of the KEYNOTE-199 trial, the importance of combination strategies in metastatic castration-resistant prostate cancer, and the next phase of research for the combination.

Neeraj Agarwal, MD, discusses the design of cohort 6 in the phase Ib COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.

Anis Hamid, MBBS, discusses the analysis of genomic profiling from the phase III CHAARTED trial, and the burgeoning potential of precision medicine in metastatic hormone sensitive prostate cancer.

Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.

Leonard G. Gomella, MD, discusses the state of genetic testing in prostate cancer, shares his recommendations for screening, and provides perspective on where the field is headed.

In a recent study, investigators at UCLA and UCSF have demonstrated high positive predictive value for a new imaging technique for localizing recurrent prostate cancer.

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).